Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Depreciation & Amortization (CF) of $23688.0 for Q3 2025, up 260.66% year-over-year from $6568.0 in Q3 2024, and down 1.94% quarter-over-quarter from $24157.0 in Q2 2025.
Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $23688.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) rose 260.66% year-over-year to $23688.0; the TTM figure through Mar 2026 stood at $47845.0 (up 47.86% YoY), while the FY2025 annual figure was $60499.0, up 130.28% from the prior year.
- Depreciation & Amortization (CF) fell to $23688.0 in Q3 2025 per IKT's latest filing, from $24157.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $159204.0 in Q2 2023 and bottomed at $1681.0 in Q3 2022.
- Historically, Depreciation & Amortization (CF) has averaged $20836.7 across 4 years, with a median of $6568.0 in 2023.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 290.72% — and 2024, when it tumbled 95.87%.
- Inhibikase Therapeutics' Depreciation & Amortization (CF) stood at $5042.0 in 2022, then jumped by 30.27% to $6568.0 in 2023, then retreated by 0.02% to $6567.0 in 2024, then surged by 260.71% to $23688.0 in 2025.
- Business Quant data shows IKT's Depreciation & Amortization (CF) at $23688.0 in Q3 2025, $24157.0 in Q2 2025, and $12654.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 23,688.00 |
| Sep 30, 2025 | 23,688.00 |
| Jun 30, 2025 | 24,157.00 |
| Jun 30, 2025 | 24,157.00 |
| Mar 31, 2025 | 12,654.00 |
| Mar 31, 2025 | 12,654.00 |
| Dec 31, 2024 | 6,567.00 |
| Dec 31, 2024 | 6,567.00 |
| Sep 30, 2024 | 6,568.00 |
| Sep 30, 2024 | 6,568.00 |
| Jun 30, 2024 | 6,569.00 |
| Jun 30, 2024 | 6,569.00 |
| Mar 31, 2024 | 6,568.00 |
| Mar 31, 2024 | 6,568.00 |
| Dec 31, 2023 | 6,568.00 |
| Dec 31, 2023 | 6,568.00 |
| Sep 30, 2023 | 6,568.00 |
| Sep 30, 2023 | 6,568.00 |
| Jun 30, 2023 | 159,204.00 |
| Jun 30, 2023 | 159,204.00 |